FDA Approval of Brexucabtagene Autoleucel for B-Cell ALL: Bijal Shah, MD, MS

Video

The hematologist from Moffitt Cancer Center discussed the FDA approval of brexucabtagne autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Bijal Shah, MD, MS, associate member, Department of Malignant Hematology, Moffitt Cancer Center, to learn more about his thoughts on the FDA approval of brexucabtagene autoleucel (Tecartus) for patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

Brexucabtagene autoleucel was approved by the FDA on October 1, 2021 for patients with relapsed/refractory B-cell precursor ALL. The approval was based on findings from the phase 1/2 ZUMA-3 trial (NCT02614066), which demonstrated a complete remission (CR; CR + CR with incomplete platelet recovery) rate of 71% (95% CI, 57%-82%; 56% CR, 15% CRi). Thirty-one percent of responders had ongoing responses. The median duration of response, relapse-free survival, and overall survival was 12.8 months (95% CI, 8.7-not estimable [NE]), 11.6 months (95% CI, 2.7-15.5), and 18.2 months (95% CI, 15.9-NE), respectively.

These data, apart from powerful, are unheard of in such a heavily pretreated population of patients with ALL, says Shah. The magnitude of OS benefit seen with brexucabtagene autoleucel in this patient population has never been achieved in prior trials in this setting, marking a significant advance for the field, concludes Shah.

Related Videos
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.